DNLI
Price
$14.69
Change
-$0.21 (-1.41%)
Updated
Jul 3 closing price
Capitalization
2.13B
25 days until earnings call
SYBX
Price
$1.18
Change
-$0.02 (-1.67%)
Updated
Jul 3 closing price
Capitalization
13.8M
Interact to see
Advertisement

DNLI vs SYBX

Header iconDNLI vs SYBX Comparison
Open Charts DNLI vs SYBXBanner chart's image
Denali Therapeutics
Price$14.69
Change-$0.21 (-1.41%)
Volume$613.31K
Capitalization2.13B
Synlogic
Price$1.18
Change-$0.02 (-1.67%)
Volume$18.83K
Capitalization13.8M
DNLI vs SYBX Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. SYBX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and SYBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (DNLI: $14.69 vs. SYBX: $1.18)
Brand notoriety: DNLI and SYBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 42% vs. SYBX: 189%
Market capitalization -- DNLI: $2.13B vs. SYBX: $13.8M
DNLI [@Biotechnology] is valued at $2.13B. SYBX’s [@Biotechnology] market capitalization is $13.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 0 green, 5 red.
According to our system of comparison, SYBX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while SYBX’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • SYBX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYBX is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.38% price change this week, while SYBX (@Biotechnology) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

SYBX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.13B) has a higher market cap than SYBX($13.8M). SYBX YTD gains are higher at: -15.714 vs. DNLI (-27.920). SYBX has higher annual earnings (EBITDA): -13.66M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. SYBX (17.3M). SYBX has less debt than DNLI: SYBX (0) vs DNLI (48.6M). DNLI (0) and SYBX (0) have equivalent revenues.
DNLISYBXDNLI / SYBX
Capitalization2.13B13.8M15,464%
EBITDA-505.16M-13.66M3,699%
Gain YTD-27.920-15.714178%
P/E RatioN/A5.36-
Revenue00-
Total Cash818M17.3M4,728%
Total Debt48.6M0-
FUNDAMENTALS RATINGS
DNLI vs SYBX: Fundamental Ratings
DNLI
SYBX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9446
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
9945
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYBX's Valuation (86) in the Biotechnology industry is in the same range as DNLI (93). This means that SYBX’s stock grew similarly to DNLI’s over the last 12 months.

SYBX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that SYBX’s stock grew similarly to DNLI’s over the last 12 months.

SYBX's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that SYBX’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's Price Growth Rating (60) in the Biotechnology industry is in the same range as SYBX (61). This means that DNLI’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for DNLI (99). This means that SYBX’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLISYBX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LYEL9.690.26
+2.76%
Lyell Immunopharma Inc
LITE92.751.51
+1.65%
Lumentum Holdings
DTE131.941.26
+0.96%
DTE Energy Company
TRVI5.95-0.03
-0.50%
Trevi Therapeutics
SSKN2.33-0.25
-9.69%
Strata Skin Sciences

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.41%
BEAM - DNLI
58%
Loosely correlated
+0.65%
NRIX - DNLI
57%
Loosely correlated
+2.33%
OCUL - DNLI
55%
Loosely correlated
+1.69%
RGNX - DNLI
55%
Loosely correlated
+1.39%
ARWR - DNLI
55%
Loosely correlated
-0.65%
More

SYBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYBX has been loosely correlated with NEUP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SYBX jumps, then NEUP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYBX
1D Price
Change %
SYBX100%
-1.67%
NEUP - SYBX
64%
Loosely correlated
+1.57%
BTAI - SYBX
37%
Loosely correlated
N/A
SBHMY - SYBX
34%
Loosely correlated
N/A
MDGL - SYBX
31%
Poorly correlated
-0.43%
DNLI - SYBX
29%
Poorly correlated
-1.41%
More